Back to search

Article

SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques

2021-01-30

Abstract excerpt

The first COVID-19 vaccines have recently gained authorization for emergency use. 1,2 At this moment, limited knowledge on duration of immunity and efficacy of these vaccines is available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short lived, 3,4 and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. 5 Here we model the r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cb43f9a0-7524-5743-b427-40c9317e965d
DOI
10.1101/2021.01.30.428921
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaquesDOI 10.1101/2021.01.30.428921
Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaquesSemantic proximity
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaquesSemantic proximity
Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA VaccinationSemantic proximity
SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity
Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2Semantic proximity
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.Semantic proximity
An intranasal vaccine durably protects against SARS-CoV-2 variants in miceSemantic proximity
Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosingSemantic proximity
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaquesSemantic proximity
SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concernSemantic proximity
Beta variant COVID-19 protein booster vaccines elicit durable cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity
Select a neighboring publication to make it the new centre.